Palejwala Neal V, Lauer Andreas K, Weleber Richard G
Oregon Retinal Degeneration Center (ORDC), Ophthalmic Genetics Service and Retina-Vitreous Service, Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA.
Clin Ophthalmol. 2014 Sep 1;8:1675-9. doi: 10.2147/OPTH.S68243. eCollection 2014.
To report a rare case of central vision loss in a patient with choroideremia.
A retrospective, interventional case report.
A 13-year-old male with history of choroideremia presented with subacute loss of central acuity in his left eye. Examination and diagnostic testing revealed subretinal fibrosis secondary to a choroidal neovascular membrane (CNVM). A trial of anti-vascular endothelial growth factor (VEGF) therapy with the injection of intravitreal bevacizumab was attempted. Mild improvements in acuity and anatomy were noted.
Choroideremia is a rare hereditary choroidal dystrophy that predominantly affects males in the first and second decades of life. Visual acuity is usually spared until later in life. CNVM is a rare manifestation of choroideremia with only a handful of case reports presented in the literature. This case is unique in that it is the first reported case that received treatment with intravitreal anti-VEGF therapy.
报告1例脉络膜视网膜变性患者出现中心视力丧失的罕见病例。
一项回顾性介入病例报告。
一名有脉络膜视网膜变性病史的13岁男性，左眼出现亚急性中心视力丧失。检查和诊断测试显示继发于脉络膜新生血管膜（CNVM）的视网膜下纤维化。尝试了玻璃体内注射贝伐单抗进行抗血管内皮生长因子（VEGF）治疗试验。视力和眼部结构有轻度改善。
脉络膜视网膜变性是一种罕见的遗传性脉络膜营养不良，主要影响10至20岁的男性。视力通常在生命后期才会受到影响。CNVM是脉络膜视网膜变性的一种罕见表现，文献中仅有少数病例报告。该病例独特之处在于，它是首例接受玻璃体内抗VEGF治疗的报告病例。
